Compare DLB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLB | APLS |
|---|---|---|
| Founded | 1965 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.2B |
| IPO Year | 2004 | 2015 |
| Metric | DLB | APLS |
|---|---|---|
| Price | $63.93 | $40.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 21 |
| Target Price | ★ $90.75 | $33.59 |
| AVG Volume (30 Days) | 459.3K | ★ 9.1M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | ★ 0.55 | 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $3.84 | $18.19 |
| P/E Ratio | ★ $116.35 | $204.63 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $57.62 | $16.10 |
| 52 Week High | $78.28 | $40.95 |
| Indicator | DLB | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 87.20 |
| Support Level | $63.91 | $19.29 |
| Resistance Level | $64.87 | $40.95 |
| Average True Range (ATR) | 1.23 | 0.08 |
| MACD | 0.26 | -0.53 |
| Stochastic Oscillator | 71.17 | 96.77 |
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).